These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24364858)

  • 1. Susceptibility of intracellular Coxiella burnetii to antimicrobial peptides in mouse fibroblast cells.
    Unsworth NB; Dawson RM; Wade JD; Liu CQ
    Protein Pept Lett; 2014; 21(2):115-23. PubMed ID: 24364858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotransmitter System-Targeting Drugs Antagonize Growth of the Q Fever Agent, Coxiella burnetii, in Human Cells.
    Fullerton MS; Colonne PM; Dragan AL; Brann KR; Kurten RC; Voth DE
    mSphere; 2021 Aug; 6(4):e0044221. PubMed ID: 34232075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of rifapentine and other rifamycins against
    Miller HK; Kersh GJ
    Microbiol Spectr; 2024 Jul; 12(7):e0103424. PubMed ID: 38864598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meso-tartrate inhibits intracellular replication of Coxiella burnetii, the causative agent of the zoonotic disease Q fever.
    Bitew MA; Wawegama NK; Newton HJ; Sansom FM
    Pathog Dis; 2019 Nov; 77(8):. PubMed ID: 31845968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of pH on Antibiotic Efficacy against Coxiella burnetii in Axenic Media.
    Smith CB; Evavold C; Kersh GJ
    Sci Rep; 2019 Dec; 9(1):18132. PubMed ID: 31792307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine susceptibility determination of Coxiella burnetii in human embryonic lung (HEL) fibroblast cells.
    Angelakis E; Khalil JB; Le Bideau M; Perreal C; La Scola B; Raoult D
    Int J Antimicrob Agents; 2017 Jul; 50(1):106-109. PubMed ID: 28478211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Cholesterol in the
    Mulye M; Samanta D; Winfree S; Heinzen RA; Gilk SD
    mBio; 2017 Feb; 8(1):. PubMed ID: 28246364
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of axenic media to determine antibiotic efficacy against coxiella burnetii.
    Clay KA; Hartley MG; Russell P; Norville IH
    Int J Antimicrob Agents; 2018 May; 51(5):806-808. PubMed ID: 28802854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.
    Gikas A; Spyridaki I; Scoulica E; Psaroulaki A; Tselentis Y
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3276-8. PubMed ID: 11600400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis.
    Rolain JM; Boulos A; Mallet MN; Raoult D
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2673-6. PubMed ID: 15980335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
    Spyridaki I; Psaroulaki A; Vranakis I; Tselentis Y; Gikas A
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2690-2. PubMed ID: 19332671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Coxiella burnetii antibiotic susceptibilities by real-time PCR assay.
    Brennan RE; Samuel JE
    J Clin Microbiol; 2003 May; 41(5):1869-74. PubMed ID: 12734219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cationic antimicrobial peptide enhances the infectivity of Coxiella burnetii.
    Aragon AS; Pereira HA; Baca OG
    Acta Virol; 1995 Sep; 39(4):223-226. PubMed ID: 8825304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA gyrase and topoisomerase IV mutations in an in vitro fluoroquinolone-resistant Coxiella burnetii strain.
    Vranakis I; Sandalakis V; Chochlakis D; Tselentis Y; Psaroulaki A
    Microb Drug Resist; 2010 Jun; 16(2):111-7. PubMed ID: 20438350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility to tetracycline and fluoroquinolones of Japanese isolates of Coxiella burnetii.
    Andoh M; Naganawa T; Yamaguchi T; Fukushi H; Hirai K
    Microbiol Immunol; 2004; 48(9):661-4. PubMed ID: 15383702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coxiella burnetii alters cyclic AMP-dependent protein kinase signaling during growth in macrophages.
    MacDonald LJ; Kurten RC; Voth DE
    Infect Immun; 2012 Jun; 80(6):1980-6. PubMed ID: 22473604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of telithromycin against thirteen new isolates of C. burnetii including three resistant to doxycycline.
    Rolain JM; Lambert F; Raoult D
    Ann N Y Acad Sci; 2005 Dec; 1063():252-6. PubMed ID: 16481522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic susceptibilities of two Coxiella burnetii isolates implicated in distinct clinical syndromes.
    Yeaman MR; Roman MJ; Baca OG
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1052-7. PubMed ID: 2782856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid A Has Significance for Optimal Growth of
    Wang T; Yu Y; Liang X; Luo S; He Z; Sun Z; Jiang Y; Omsland A; Zhou P; Song L
    Front Cell Infect Microbiol; 2018; 8():192. PubMed ID: 29938202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-10 stimulates Coxiella burnetii replication in human monocytes through tumor necrosis factor down-modulation: role in microbicidal defect of Q fever.
    Ghigo E; Capo C; Raoult D; Mege JL
    Infect Immun; 2001 Apr; 69(4):2345-52. PubMed ID: 11254592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.